A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Sarina A Piha-Paul Shane A Olwill Erika Paige Hamilton Anthony W Tolcher Paula R Pohlmann Stephen V Liu Cornelia Wurzenberger Laura-Carolin Hasenkamp Eva-Maria Hansbauer Rachna T Shroff Sara Alsterlind Hurvitz Anuradha Krishnamurthy Amita Patnaik Noah M Hahn Raman Kumar Manuela Duerr Markus Zettl Kayti Aviano Louis Matis Ingmar Bruns Geoffrey Y Ku

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Cinrebafusp alfa demonstrates promising activity in patients with HER2-positive malignancies who have progressed on prior HER2-targeting regimens. Its acceptable safety profile suggests it could be a treatment option for patients not responding to existing HER2-directed therapies.

Keyphrases

end stage renal disease
endothelial cells
replacement therapy
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
growth factor
pluripotent stem cells